Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today the company’s rebranding to Cellphire Therapeutics, Inc. The significant rebrand includes a new logo and website.
At the heart of the rebrand is the company’s name change to Cellphire Therapeutics, a name that reflects the company’s vision—to be the world leader in platelet- and other cell-based therapeutics. In addition to the name change, the new website provides expanded insight into the company’s products and research.
The changes come at an exciting new phase for the company as its clinical research moves into Phase 2 clinical trials in bleeding patients for its lead product Thrombosomes®, funded by the Biomedical Advanced Research and Development Authority (BARDA) and for Cryopreserved Platelets (CPP), funded by the U.S. Army. Thrombosomes® is the only platelet-based freeze-dried hemostatic agent in clinical trials. The product has the potential to transform transfusion medicine with its shelf stability of 3 years. In addition, Cellphire is developing CPP, frozen platelets, for the U.S. Army to fill a gap in military transfusion support. CPP is a complementary product to Cellphire’s next-generation product, Thrombosomes®.
“Cellphire has grown significantly over the past 16 years, and it is time to reflect that growth and our success in our brand identity,” said Rafael Jorda, Interim CEO, Cellphire Therapeutics. “We feel this new brand identity and website more accurately represents the company—now and as we expand in the future—and we are excited to share our new look and provide more insight into our work.”
About Cellphire Therapeutics
Cellphire Therapeutics is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to platelets to develop lifesaving products. Its lead product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical applications—from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine.
The Thrombosomes project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021.
The work on CPP is supported by the U.S. Army Medical Research and Development Command under Contract No. W81XWH20C0030.
The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Chief Investment Officer